MIRA

Mira Pharma

• Reuters·5d ago

  Mira Pharmaceuticals investor presentation highlights Ketamir-2 advancing to Phase 2a neuropathic pain trial

• Benzinga·03/24 13:22

  What's Going On With MIRA Pharma Stock Tuesday?

• Benzinga·03/24 12:05

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• Benzinga·03/23 17:05

  12 Health Care Stocks Moving In Monday's Intraday Session

• TipRanks·03/23 13:41

  MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55

• TipRanks·03/23 13:20

  Mira reports Mira-55 shows no THC-, Rimonabant-associated CNS side effects

• Benzinga·03/23 13:03

  MIRA Pharma Announces New Preclinical Data Demonstrating Mira-55 Did Not Produce Cannabinoid-Like CNS Side Effects Across Comprehensive Battery Of Validated Behavioral Assays

• Reuters·03/23 13:00

  Mira Pharmaceuticals reports preclinical study finds Mira-55 shows no THC-like CNS side effects

• Reuters·03/04 13:01

  MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

• TipRanks·03/03 21:44

  MIRA Completes Phase 1 Trial of Ketamir-2 Therapy

• Benzinga·03/03 21:33

  Mira Pharmaceuticals Completes Patient Dosing In Phase 1 Clinical Study Of Ketamir-2; No Serious Adverse Events, Dose-Limiting Toxicities Seen; Plans To File Phase 2a Clinical Trial, Supporting Documents To FDA In H1

• Reuters·03/03 21:28

  MIRA PHARMACEUTICALS- NO CLINICALLY SIGNIFICANT DISSOCIATIVE OR PSYCHOTOMIMETIC EFFECTS OBSERVED IN PHASE 1 TRIAL OF KETAMIR-2 - SEC FILING

• Benzinga·03/03 21:05

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• Reuters·02/06 16:27

  Mira Pharmaceuticals Unveils Pipeline Focused on Oral Therapies for Neurologic and Metabolic Disorders